NCT04541082 2025-12-18Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsJazz PharmaceuticalsPhase 1 Recruiting102 enrolled
NCT04337177 2025-09-23Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLCPhase 1 Recruiting20 enrolled